- Déficit Androgénique Lié À L’âge
- Published:
Androgènes et qualité de vie
Androgens and quality of life
Andrologie volume 12, pages 257–261 (2002)
Résumé
Les manifestations cliniques associées au syndrome du déclin androgénique lié à l’âge altèrent la qualité de la vie. Outre les troubles sexuels, des symptômes fonctionnels, des troubles neuropsychiques ainsi que des modifications morphologiques et de l’image de soi participent à cette altération. La testostérone a un impact bénéfique sur la composition corporelle. Son effet anabolisant participe à l’amélioration de la sensation de bien-être par la diminution de la masse grasse, l’augmentation de la masse et de la force musculaire. Des effets directs de la testostérone sur le système nerveux central peuvent aussi participer à l’amélioration de la sensation de bien-être, de la qualité du sommeil et des fonctions cognitives que l’on observe lors de traitements substitutifs. Par contre, des doses supra physiologiques peuvent induire des réactions agressives ou maniaques.
Abstract
Clinical manifestations of androgenic deficiency in the ageing male induce deterioration of quality of life. In addition to sexual disorders, functional and neuropsychiatric symptoms, and morphological changes affecting the self-image participate in this deterioration. Testosterone has a beneficial impact on body composition. The anabolic effects of testosterone help to improve the feeling of well-being by reducing fat mass, and increasing muscle mass and strength. The direct effects of testosterone on the central nervous system may also participate in the improvement of the feeling of well-being, the quality of sleep and cognitive functions, as observed during hormone replacement therapy. However, administration of supraphysiological doses of testosterone can induce aggressive reactions and manisc episodes.
Références
BAGATELL C.J., BREMNER W.J.: Androgens in men-uses and abuses. N. Engl. J. Med., 1996, 334: 707–714.
BHASIN S., STORER T.W., BERMAN N., et al.: The effects of supraphysiologic doses of testosterone on muscle size and strength in men. N. Engl. J. Med., 1996, 335: 1–7.
BHASIN S., BAGATELL C.J., BREMNER W.J., et al.: Issues in testosterone replacement in older men. J. Clin. Endocrinol. Metab., 1998, 83: 3435–3448.
BARDIN C.W., SWERDLOFF R.S., SANTEN R.J.: Androgens: risks and benefits. J. Clin. Endocrinol. Metab., 1991, 73: 4–7.
GRAY A., FELDMAN H.A., Mc KINLAY J.B., LONGCOPE C.: Age, disease and changing sex hormone levels in midle-aged men: results of the Massachusetts male aging study. J. Clin. Endocrinol. Metab., 1991, 73: 1016–1025.
GRINSPOON S., CORCORAN C., STANLEY T., BAAJ A., BASGOZ N., KLIBANSKI A.: Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J. Clin. Endocrinol. Metab., 2000, 85: 60–65.
HAJJAR R.R., KAISER F.E., MORLEY J.E.: Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J. Clin. Endocrinol. Metab., 1997, 82: 3793–3796.
HANNAN C.J. Jr., FRIEDL K.E., ZOLD A., KETTLER T.M., PLYMATE S.R.: Psychological and serum homovanillic acid changes in men administered androgenic steroids. Psychoneuroendocrinology, 1991, 16: 335–343.
HAYES F.J.: Testosterone-fountain of youth or drug of abuse? J. Clin. Endocrinol. Metab., 2000, 85: 3020–3023.
LEGROS J.J.: Vers un consensus pour le traitement androgénique substitutif de l’andropause. Rev. Med. Liège, 2000, 55: 449–453.
MORALES A.J., NOLAN J.J., NELSON J.C., YEN S.S.: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab., 1994, 78: 1360–1367.
MORLEY J.E., PERRY H.M. 3rd, KAISER F.E., KRAENZLE D. et al.: Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc., 1993, 41: 149–152.
PERRY P.J., ANDERSEN K.H., YATES W.R.: Illicit anabolic steroid use in athletes. A case series analysis. Am. J. Sports Med., 1990, 18: 422–428.
POPE H.G. Jr, KOURI E.M., HUDSON J.I.: Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch. Gen. Psychiatry, 2000, 57: 133–140.
REYES-ORTEGA G., NOURHASHEMI F., VELLAS B., ALBAREDE J.L.: Traitement androgène chez le sujet agé, revue de la littérature. L’année gérontologique, 1997, 11: 377–389.
RITCHIE C.S., BURGIO K.L., LOCHER L.J., et al.: Nutritional status of urban homebound older adults. Am. J. Clin. Nutr., 1997, 66: 815–818.
SCHLIENGER J.L.: L’andropause existe: mais comment la traiter? Rev. Prat., 2001, 15: 277–281.
SNYDER P.J., PEACHEY H., HANNOUSH P. et al.: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab., 1999, 84: 2647–2653.
SU T.P., PAGLIARO M., SCHMIDT P.J., PICKAR D., WOLKOWITZ O., RUBINOW D.R.: Neuropsychiatric effects of anabolic steroids in male normal volunteers. J. Am. Med. Ass., 1993, 269: 2760–2764.
TENOVER J.S.: Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab., 1992, 75: 1092–1098.
TRICKER R., CASABURI R., STORER T.W., et al.: The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men-a clinical research center study. J. Clin. Endocrinol. Metab., 1996, 81: 3754–3758.
WANG C., ALEXANDER G., BERMAN N., et al.: Testosterone replacement therapy improves mood in hypogonadal men-a clinical research center study. J. Clin. Endocrinol. Metab., 1996, 81: 3578–3583.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mimoun, S. Androgènes et qualité de vie. Androl. 12, 257–261 (2002). https://doi.org/10.1007/BF03035136
Issue Date:
DOI: https://doi.org/10.1007/BF03035136